Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma.
Zhu Y, Ke KB, Xia ZK, Li HJ, Su R, Dong C, Zhou FM, Wang L, Chen R, Wu SG, Zhao H, Gu P, Leung KS, Wong MH, Lu G, Zhang JY, Jiang BH, Qiu JG, Shi XN, Lin MC.
Zhu Y, et al. Among authors: qiu jg.
Mol Med. 2021 Feb 12;27(1):15. doi: 10.1186/s10020-021-00269-4.
Mol Med. 2021.
PMID: 33579185
Free PMC article.